Market Overview

UPDATE: Piper Jaffray Cuts PT to $27 on Impax Laboratories on Rytary Launch Visibility

Share:
Related IPXL
Benzinga's Top Initiations
Impax Receives FDA Approval for Generic Version of Intuniv Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg
Vertex Pharmaceuticals Has Great Upside Potential (Seeking Alpha)

Piper Jaffray maintained Impax Laboratories (NASDAQ: IPXL) with an Overweight rating and lowered the price target from $29.00 to $27.00.

Piper Jaffray commented, "With a compelling net cash position of now close to $460M... in the context of a $1.3B market cap and 2013 operating cash flows pushing the cash position well north of $7 per share (near 40% of IPXL's market cap), we believe the risk/reward profile of IPXL shares is attractive. We reiterate our Overweight rating and are lowering our PT to $27 from $29. … We have lowered our price target from $29 to $27 based on 20x (up from 14x) our 2015E EPS of $1.61 (previously 2014E EPS of $2.06), discounted by 20% for 1 year (previously undiscounted) … given the continued uncertainty regarding the timing of a warning letter resolution and subsequent launches of Rytary and several key generic products."

Impax Laboratories closed at $19.62 on Monday.

Latest Ratings for IPXL

DateFirmActionFromTo
Jan 2016JP MorganInitiates Coverage onNeutral
Oct 2015BTIG ResearchInitiates Coverage onBuy
Sep 2015NomuraInitiates Coverage onNeutral

View More Analyst Ratings for IPXL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (IPXL)

View Comments and Join the Discussion!

Get Benzinga's Newsletters